Medinol Adopts “Trojan Horse” Strategy To Beat Drug-Eluting Stents
This article was originally published in The Gray Sheet
Executive Summary
Medinol will begin pilot clinical trials by the end of 2002 on an anti-restenosis drug delivery technology intended as an alternative to drug-eluting stents
You may also be interested in...
Medtronic Broadens Drug Delivery Options With EndoBionics Purchase
Medtronic's equity investment in privately held EndoBionics for injectable drug delivery technology complements Medtronic's existing drug-eluting stent platform
Medtronic Broadens Drug Delivery Options With EndoBionics Purchase
Medtronic's equity investment in privately held EndoBionics for injectable drug delivery technology complements Medtronic's existing drug-eluting stent platform
FDA Panel Review Of J&J Cypher Stent Will Weigh SIRIUS Late Loss Data
Johnson & Johnson/Cordis' upcoming presentation before an FDA advisory panel on the Cypher drug-eluting stent will highlight a 67% reduction of target vessel failure (TVF) at nine months compared with bare stents